Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04755283 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
A Phase 2 study of Stroke and Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 1,287
- Enrollment target
- 20
- Study locations
NCT04755283: Active Phase 2 study of Stroke and Atrial Fibrillation (AF), sponsored by Anthos Therapeutics.
NCT04755283 is a Phase 2 study of Stroke and Atrial Fibrillation (AF) that is active but no longer recruiting, run by Anthos Therapeutics. The registered enrollment target is 1,287 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04755283, a Phase 2 study of Stroke and Atrial Fibrillation (AF), is active but no longer recruiting, sponsored by Anthos Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,287 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Primary Outcome
The number of participants experiencing the first occurrence of the composite of ISTH-defined major bleeding or CRNM bleeding events divided by the number of 100 person-years through the first event or end of treatment across all participants, is presented. For participants not experiencing events, person-years is calculated through the end of treatment during the randomized phase.
Conditions Studied
Interventions
- BIOLOGICAL Abelacimab
- DRUG Rivaroxaban
Study Locations (20)
Florida
- Anthos Investigative Site - Clearwater
- Anthos Investigative Site - Daytona Beach
- Anthos Investigative Site - Largo
- Anthos Investigative Site - Safety Harbor
- Anthos Investigative Site - Saint Augustine
Alabama
- Anthos Investigative Site - Huntsville
- Anthos Investigative Site - Mobile
Maryland
- Anthos Investigative Site - Baltimore
- Anthos Investigative Site - Salisbury
Massachusetts
- Anthos Investigative Site - Framingham
- Anthos Investigative Site - Haverhill
New York
- Anthos Investigative Site - Poughkeepsie
- Anthos Investigative Site - Southampton
Connecticut
- Anthos Investigative Site - Stamford
Georgia
- Anthos Investigative Site - Johns Creek
Kentucky
- Anthos Investigative Site - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,287 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2028-12-29 |
| Phase | Phase 2 |
What the registry record for NCT04755283 still lists
NCT04755283 is an interventional study that assigns participants to a tested intervention. Its 1,287 participants enrollment target places it among the larger protocols in the corpus, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 2 interventions - of which Abelacimab is the first listed.
NCT04755283 names 20 study sites across 12 states, led by Florida, Alabama, Maryland.
Frequently Asked Questions
What is clinical trial NCT04755283 about?
NCT04755283 is a clinical study titled "Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation". The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
What is the current status of trial NCT04755283?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,287 participants. The study started on 2021-02-02. Estimated completion is 2028-12-29.
What conditions does trial NCT04755283 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation (AF).
What interventions are being tested in trial NCT04755283?
The interventions under investigation include: Abelacimab (BIOLOGICAL), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT04755283?
This trial is sponsored by Anthos Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04755283 being conducted?
This trial has 20 study locations across Alabama, Connecticut, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04755283's enrollment target sits among peer trials
1,287 31st of 454 higher than 424 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI